Floatz logo

Atg-010

Peripheral T-cell Lymphoma

Antengene CorporationPhase 1/2Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
25/ 100
Competitive Position
73/ 100

Competitive context

39 Active assets in the Peripheral T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Inno-206
BeBetter Med Inc
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

Atg-010 is also rated in:

relapsed/refractory diffuse large B-cell lymphomaDormant
CCC
Indicative ·
49 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
45 / 100
View asset →
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical CancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →